Page 89 - MEMOCiberer014-ENG

Most relevant scientific articles
• sancHez-araGo m, Garcia-bermuDez J, martinez-reyes i, santacatterina F, cuezVa Jm . Degradation of IF1 controls energy metabolism during osteogenic differentiation of stem cells . EMBO Rep . 2013;14(7):638-44 .
• sancHez-araGo m, Formentini l, cuezVa Jm . Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors . Antioxid Redox Signal . 2013;19(3):285-98 .
• martínez-reyes i, cuezVa Jm . The H(+)-ATP synthase: a gate to ROS-mediated cell death or cell survival . Biochim Biophys Acta . 2014;1837(7)
• Formentini l, pereira mp, sancHez-cenizo l, santacatterina F, lucas JJ, naVarro c, et al . In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning . Embo J . 2014;33(7):762-78 .
• santacatterina F, cHamorro m, De arenas cn, naVarro c, martín ma, cuezVa Jm, sáncHez-araGó m . Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases . J Transl Med . 2015;13:424 .
Highlights
Institution: Universidad Autónoma de Madrid Contact: Centro de Biologia Molecular Severo Ochoa . Nicolás Cabrera, 1 Campus de Cantoblanco UAM, 28049 Madrid · Phone: (+34) 91 196 46 18 / 91 196 46 48 E .mail: jmcuezva@cbm .csic .es http://www .cbm .uam .es/mkfactory .esdomain/webs/CBMSO/plt_LineasInvestigacion .aspx?IdObjeto=7
PROJECTS
• Reference: S2010/BMD-2402. Title: La mitocondria y su implicación en patología humana. Budget: 795.800€. 2012-2015. PI: José M. Cuezva Marcos. • Reference: 13-713/438.00. Title: Traslational Research, experimental Medicine and Therapeutics on Charcot-Marie-Tooth disease (TREAT-CMT) . International Rare Diseases Research Consortium (IRDiRC). Budget: 3.084.664€. 2012-2016. Co-PI: José M. Cuezva Marcos. • Reference: SAF2013- 41945-R . Title: La mitocondria y su disfunción en patología: papel de IF1 . Budget: 335000€ . 2014-2016 . PI: José M. Cuezva Marcos. • Reference: Fundación Ramón Areces. Title: Función oncogénica de IF1, el inhibidor de la H+ATP sintasa de la mitocondria . Budget: 125760€ . 2015-2017 . PI . José M . Cuezva Marcos .
PATENTS
• Inventors: Fulvio Santacatterina, María Sánchez-Aragó and José M. Cuezva. Title: “Un proceso y kit para el diag- nóstico diferencial de una enfermedad que cursa con afectación muscular” . Application number: 201230771 . Publication number: ES2432653 . Country: Spain . Publication date: 23/05/2012 . Applicants: Universidad Au- tónoma de Madrid-CIBERER. • BRAND REGISTRY NUMBER: PROTEOmAb. Owner: Universidad Autónoma de Madrid. Brand number: 3.055.803. Application date: 12/12/2012. Authorization date: 14/03/2013. • The lab has developed PROTEOmAb Platform, focused on the identification and quantification of new disease molecular markers and/or therapy response . Based on “Reverse Phase Protein Microarray” technology . Analysis of 1 .000 different biopsies, that provides correlations with clinical and treatment response parameters . (i) “Translation of Energy Metabolism” group in Cancer field of the Instituto de Investigación Hospital 12 de Octubre (i+12) (ii) We belong to MITOLAB Consortium, Comunidad de Madrid . J .M . Cuezva is the Coordinator .
ABSTRACT OF SELECTED PUBLICATIONS
• We have demonstrate that the ATPase Inhibitory Factor 1 (IF1) is a potential therapeutic target in muscular mi- tochondriopathies (J Trans Med, 2015) . In a transgenic mouse model the expression of IF1 in neurons inhibits oxidative phosphorylation and regulates the activity of aerobic glycolysis . Our findings provide the first demons- tration that links the inhibition of the H+-ATP synthase with protection from neuronal damage in vivo . In the liver mouse model, we demonstrate in vivo that a metabolic phenotype with a restrained OXPHOS is prone to the development of cancer (Hepathology, 2014, submitted) .
www .ciberer .es 89